Breaking News, Financial News

Financial Report: Biogen Idec

Revenues up 32% in the quarter

Biogen Idec
 
3Q Revenues: $1.8 billion (+32%)

3Q Earnings: $488 million (+22%)

YTD Revenues: $5.0 billion (+21%)

YTD Earnings: $1.4 billion (+29%)

Comments: Growth was driven by Tysabri and new MS therapy Tecfidera, with revenues totaling $286 million in the quarter. Avonex sales were flat at $733 million. Tysabri revenues increased 46% to $401 million as a result of gaining full rights from Elan in 2Q13. Rituxan revenues from an unconsolidated joint business arrangement were $303 million in the quarter, up 5%. Royalty revenues totaled $54 million, up 15%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters